HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $10.31 million. The enterprise value is $23.14 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 1.12 million shares outstanding. The number of shares has decreased by -71.61% in one year.
| Current Share Class | 1.12M |
| Shares Outstanding | 1.12M |
| Shares Change (YoY) | -71.61% |
| Shares Change (QoQ) | +4,124.48% |
| Owned by Insiders (%) | 59.24% |
| Owned by Institutions (%) | 7.67% |
| Float | 289,935 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.00 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.00 |
Financial Efficiency
Return on equity (ROE) is -27,725.96% and return on invested capital (ROIC) is -133.70%.
| Return on Equity (ROE) | -27,725.96% |
| Return on Assets (ROA) | -52.79% |
| Return on Invested Capital (ROIC) | -133.70% |
| Return on Capital Employed (ROCE) | 2,795.87% |
| Revenue Per Employee | $40,143 |
| Profits Per Employee | -$687,573 |
| Employee Count | 36 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.14% in the last 52 weeks. The beta is 0.86, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -79.14% |
| 50-Day Moving Average | 9.55 |
| 200-Day Moving Average | 16.47 |
| Relative Strength Index (RSI) | 53.86 |
| Average Volume (20 Days) | 1,996,727 |
Short Selling Information
The latest short interest is 6,925, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 6,925 |
| Short Previous Month | 8,895 |
| Short % of Shares Out | 0.62% |
| Short % of Float | 2.39% |
| Short Ratio (days to cover) | 0.48 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $1.45 million and -$24.75 million in losses. Loss per share was -$8.76.
| Revenue | 1.45M |
| Gross Profit | 345,669 |
| Operating Income | -23.95M |
| Pretax Income | -27.39M |
| Net Income | -24.75M |
| EBITDA | -22.59M |
| EBIT | -23.95M |
| Loss Per Share | -$8.76 |
Full Income StatementBalance Sheet
The company has $1.11 million in cash and $13.94 million in debt, giving a net cash position of -$12.83 million or -$11.42 per share.
| Cash & Cash Equivalents | 1.11M |
| Total Debt | 13.94M |
| Net Cash | -12.83M |
| Net Cash Per Share | -$11.42 |
| Equity (Book Value) | -8.56M |
| Book Value Per Share | -0.19 |
| Working Capital | -25.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.14 million and capital expenditures -$131,908, giving a free cash flow of -$14.27 million.
| Operating Cash Flow | -14.14M |
| Capital Expenditures | -131,908 |
| Free Cash Flow | -14.27M |
| FCF Per Share | -$12.70 |
Full Cash Flow StatementMargins
| Gross Margin | 23.92% |
| Operating Margin | -1,657.40% |
| Pretax Margin | -1,712.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |